Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Grant of warrants

Company Announcement No. 62-2023 OrderYOYO A/SCompany announcement   Copenhagen, August 18, 2023   The board of directors of OrderYOYO has today decided to issue a total of 275,000 new warrants according to its authorisation in article 6.1 of the company’s articles of association and appendix 1 to the articles of association to three key employees.   The warrants are issued free of charge. Each warrant grants the holder a right to subscribe for one share of nominally DKK 0.01. The warrants will vest monthly over a period of four years as stipulated in the separate

DAMPSKIBSSELSKABET NORDEN A/S – weekly report on share buy-back

ANNOUNCEMENT NO. 119 - 18 AUGUST 2023 On 10 August 2023, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 10 August 2023 up to and including no later than 31 October 2023. For details, please see announcement no. 112 of 10 August 2023.   Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 30 million (approximately DKK 204 million).

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced that the U.S. Food and Drug Administration (FDA) has accepted the submission for the supplemental New Drug Application (sNDA) for TARPEYO[®] (budesonide) delayed release capsules and granted Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date is 20 December 2023.TARPEYO is currently approved under accelerated approval to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR)

Optomed to supply large diabetic retinopathy screening solution to Spain

Optomed Plc Press Release 18 August 2023 at 11.00, Helsinki Optomed to supply large diabetic retinopathy screening solution to Spain Optomed will supply diabetic retinopathy screening solution consisting of Optomed Aurora IQ fundus cameras and related software solutions to a public sector end customer in Valencia, Spain. The solution will be used to screen the local diabetic population for a potentially sight threatening disease, diabetic retinopathy. The total contract value is approximately 800 000 euros, and the delivery has a positive effect on the Devices segment’s revenue for

Interim report Q2 2023 CGit Holding AB (publ)

Mölndal.                                                                                    2023-08-18 Group financial overview Group financial 2023  2022 2023 2022 2022overview Second Second First quarter First quarter Full year quarter quarterNet sales 22 964 23 382 45 210 51 223 156 113EBITDA -1 234 286 -840 2 915 5 760Earnings (EBIT) -2 235 -677 -2 785 1 044 1 972Earnings after -2 327 -599

Notification of transactions by persons discharging managerial responsibilities and persons closely associated with them.

Company Announcement No. 18-2023Copenhagen, 18 August 2023 In accordance with the EU’s Market Abuse Regulation article 19, SameSystem A/S must publicly disclose transactions made by persons discharging managerial responsibilities and persons closely associated with them on the trading of SameSystem A/S shares. SameSystem A/S has received notification of the below transactions related to shares in SameSystem A/S made by CEO Carsten Fensholt, who has acquired 3,002,667 shares in SameSystem A/S at an average price of DKK 1.194 per share. Carsten Fensholt now personally owns 6,683,

Scandinavian ChemoTech’s subsidiary for Animal Care US receives order confirmation for a vetIQure system to Ohio

VQ Animal Care Inc. has received its fourth order confirmation for a vetIQure TSE system in less than three months. This marks the 9[th ]commercial vetIQure installation this year, including the EU and Australia.This vetIQure TSE system will be delivered to a highly rated emergency veterinary and specialty hospital in Dayton, Ohio, which serves more than 20,000 patients on a yearly basis. With this installation, ChemoTech can now announce that no less than six states in the US (Florida, California, Ohio, Idaho, West Virginia and Louisiana) have the possibility to offer the Tumour

Unveiling the passion – Henrik Danielsson’s Getinge journey

Henrik Danielsson is a dedicated Getinge employee who, for nearly two decades, has played a crucial role in manufacturing washer-disinfectors, essential machines that contribute to saving lives. As Getinge’s Växjö factory celebrates its 80th anniversary, Henrik reflects on his journey, progress made, and an exciting future ahead. Henrik Danielsson, an integral part of Getinge for almost two decades, works in a team that manufactures Getinge's washer-disinfectors. With a diverse range of responsibilities, from welding and manufacturing to electrical work and testing, Henrik's

Company Announcement no. 78, 2023 – Nordea Kredit Realkreditaktieselskab drawings as per 1 October 2023

Nordea Kredit hereby announces drawings data for callable covered mortgage bonds (SDRO) as per 1 October 2023. The figures are published in order to comply with publication requirements in the transparency regulation 2017/1129/EU and the Danish Act on Capital Markets section 24.   Questions can be directed to Torben Jurlander phone +45 55 47 41 99.     Yours faithfully   Nordea Kredit Realkreditaktieselskab

AFRY and Morefish in partnership to enhance land-based aquaculture

AFRY and the Norwegian company Morefish have entered a partnership to respond to the increasing demand for expertise in land-based aquaculture projects. Together, AFRY and Morefish are spearheading the Blue Food sector by offering a comprehensive approach to clients, covering expertise from feasibility studies to farm operations, complemented by a strong focus on project management.By combining AFRY’s experience in land-based fish farms and project management, with Morefish’ expertise in fish biology and RAS technology (Recirculation Aquaculture System), the companies will support clients

Bioservo Technologies AB Interim Report January – June 2023

April-June in figures · Net sales of 1.2 MSEK (3.6) · EBITDA of -11.4 MSEK (-11.0) · EBIT of -11.9 MSEK (-11.8) · Earnings for the period amounted to -11.9 MSEK (-11.8) · Earnings per share before and after dilution amounted to SEK -0.42 (-0.62) · Cash flow from operating activities for the period amounted to – 9.5 MSEK (-9.8) January-June in figures · Net sales of 5.8 MSEK (6.5) · EBITDA of -20.3 MSEK (-21.8) · EBIT of -21.3 MSEK (-23.9) · Earnings for the period amounted to -21.3 MSEK (-23.9) · Earnings per share before and after dilution amounted

TF Bank: Monthly statistics July 2023

The total loan portfolio amounted to SEK 17,182 million at the end of July. Compared to July 2022, the loan portfolio has increased by 27 % in local currencies.  Month Jul-23 Jul-22 ChangeConsumer Lending   New lending, SEK million 462 454 2 %Credit Cards   New lending, SEK million 923 475 94 %Ecommerce Solutions   Transaction volume*, SEK million 957 654 46 %  Cumulative for the year Jan-Jul 23 Jan-Jul 22 ChangeConsumer Lending   New lending, SEK million 3,652

InCoax Networks AB Interim Report, April – June 2023

InCoax more than doubled its sales during Q2 2023 compared to the same period of last year. InCoax remains engaged in two advanced inquiries, both with great potential.Financial performance April – June 2023 · Net sales amounted to SEK 9,318,146 (4,140,375), sales in line with budget, driven by sales to a US-based FiberLAN operator. · Operating profit amounted to SEK -6,316,637 (-5,051,551), a change driven by a smaller allocation to fixed assets but compensated at the same time of a positive gross profit margin. · Earnings after tax amounted to SEK -6,472,333 (–5,076,493),

Thailand pushes foward sustainable destination at Meaningful travel showcase.

“Meaningful Travel Showcase” in Denmark and Sweden were organized by Tourism Authority of Thailand to promote Thailand as one of sustainable destinations. Over 60 participants from Denmark and Sweden’s tourism industry joined the event to meet with Mr. Yuthasak Supasorn, TAT Governor, Tourism Authority of Thailand (TAT), Ms. Thapanee Kiatphaibool, TAT Deputy Governor for Domestic Marketing and representatives from 5 regions of Thailand. The events took place in Copenhagen, Denmark on August 15 and in Stockholm, Sweden on August 17.[A group of people posing for a photo Description

MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2023

Continued strong momentum and promising signs of patient benefit in the combination study with fostrox and Lenvima[®] April – JuneFinancial summary for the quarter · Net turnover amounted to SEK 2.0 (0.5) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -26.3(-21.5) million. Basic and diluted earnings per share amounted to SEK -0.47 (-0.42) and SEK -0.47 (-0.42) respectively. · Cash flow from operating activities amounted to SEK -17.9 (-17.6) million. · Cash and cash equivalents at the end of the period amounted to SEK 82.

HydrogenPro ASA - Exercise of options and mandatory notification of trade by a primary insider

Oslo, 18 August 2023: Option holders under HydrogenPro ASA's ("HydrogenPro" or the "Company", ticker code: HYPRO) share incentive program have yesterday exercised a total of 271,875 options with a strike price of NOK 7.00 per share. The exercised option value will be settled in cash. Primary insider Karoline Aafos (CPO of the Company) has exercised 21,875 options in the Company under the share incentive program, corresponding to 21,875 shares at the strike price of NOK 7.00. Please see the attached form for further details about the transaction. On 17 August 2023, the option holders,

BioStock: Dicot gets green light for start of phase I study

Dicot now takes the next big step in the development of LIB-01. The company has received approval from the Swedish Medical Products Agency to conduct its phase I study with the drug candidate. This means that the study will start as planned in August. BioStock contacted Dicot’s CEO Elin Trampe to find out more about the study.Read the full article at biostock.se : https://www.biostock.se/en/2023/08/dicot-gets-green-light-for-start-of-phase-i-study/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Fortaco Group expands its operations in Narva, Estonia

Fortaco Group, the leading strategic partner to the heavy off-highway equipment and marine industries in Europe, providing zero emission solutions and technology, assemblies, vehicle cabins, and steel fabrications expands its operations at Business Site Narva in Estonia. Fortaco Estonia OÜ and Systemair AS the owner of the real estate housing Well Technology OÜ have signed an agreement where Fortaco Estonia OÜ expands its operations into the Well Technology building. The building is located in Narva Kadastiku Industry Park. By this deal, Fortaco Estonia extends its capacity by 8.000 m2

Heimstaden Q2 2023 Results

Highlights (figures in brackets refer to previous quarter): • Continued strong operational result, driven by stable high occupancy and like-for-like rental growth of 5.7% (5.0%) • Rental income of SEK 3.8 billion (3.7) • Net operating income margin increased to 69.0% (64.9%) • Less pronounced fair value adjustments on investment properties reported at negative 2.1% • Investment properties of SEK 347 (342) billion and 162,166 (161,000) homes • Real economic occupancy of 98.2% (98.2%) • Net LTV of 57.2% (54.9%) and ICR 2.0x (2.3x) • Initiated Icelandic asset portfolio

Heimstaden Bostad Q2 2023 Results

Highlights (figures in brackets refer to previous quarter): • Continued strong operational result, driven by stable high occupancy and like-for-like rental growth of 5.6% (4.8%) • Rental income of SEK 3.7 billion (3.6) • Net operating income margin increased to 69.0% (64.9%) • Less pronounced fair value adjustments on investment properties reported at negative 2.1% • Investment properties of SEK 340 billion (335) and 160,517 homes (159,089) • Real economic occupancy of 98.1% (98.2%) • Net LTV of 54.4% (52.7%) and ICR 2.4x (3.0x) • Obtained SEK 3 billion in secured bank

Interim report

January 1 – June 30, 2023The second quarter in figures · Net sales were TSEK 5,085 (3,726), +36%. · The loss after tax was TSEK 11,352 (9,212). · The loss per share was SEK 0.16 (0.13). · The cash flow from current operations was negative in the amount of TSEK 13,054 (9,643). · The gross margin was 65.3% (70.6%). · Electrode sales volume increased by 19% and was 11,330 (9,550) units. Repeat sales of electrodes to existing customers increased by 23%. The half year in figures · Net sales were TSEK 10,234 (7,987), +28%. · The loss after tax was TSEK 22,258 (18,

Publication of Raute Corporation’s H1 2023 Half-year Report and invitation to a briefing

Raute Corporation, Investor news, 18 August 2023Publication of Raute Corporation’s H1 2023 Half-year Report and invitation to a briefingRaute Corporation will publish its Half-year Report for January 1−June 30, 2023 on Friday, August 25, 2023 at about 8:30 a.m. Finnish time. A briefing for analysts, investors and the media will be organized on the same day August 25, 2023 at 2:00−3:00 p.m.   Venue: Scandic Simonkentta Hotel, Simonkatu 9, Helsinki.   Please inform of your participation in the briefing at the latest on Wednesday, August 23, 2023 to Raute Corporation, Eija

Implantica presents the second quarter 2023 on August 24 at 15:00 CET

Implantica AG (publ) invites investors to a presentation of the second quarter 2023 at 15:00 CET on August 24. The interim report for the second quarter will be published at 8:00 a.m. CET on the same day.The presentation will be in English via an audiocast with teleconference: If you wish to participate via webcast, please use the following link: · https://ir.financialhearings.com/implantica-q2-2023 If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the

There are no items matching the current filter
There are no more items matching the current filter
Back to top